113 results on '"Llovet, Josep M."'
Search Results
2. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B
- Author
-
Moctezuma-Velázquez, Carlos, Lewis, Sara, Lee, Karen, Amodeo, Salvatore, Llovet, Josep M., Schwartz, Myron, Abraldes, Juan G., and Villanueva, Augusto
- Published
- 2021
- Full Text
- View/download PDF
3. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
- Author
-
Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., and Zhu, Andrew X.
- Published
- 2021
- Full Text
- View/download PDF
4. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma
- Author
-
Puigvehí, Marc, Moctezuma-Velázquez, Carlos, Villanueva, Augusto, and Llovet, Josep M.
- Published
- 2019
- Full Text
- View/download PDF
5. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- Author
-
Llovet, Josep M., Montal, Robert, and Villanueva, Augusto
- Published
- 2019
- Full Text
- View/download PDF
6. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- Author
-
Galle, Peter R., Forner, Alejandro, Llovet, Josep M., Mazzaferro, Vincenzo, Piscaglia, Fabio, Raoul, Jean-Luc, Schirmacher, Peter, and Vilgrain, Valérie
- Published
- 2018
- Full Text
- View/download PDF
7. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
- Author
-
Llovet, Josep M, Kudo, Masatoshi, Merle, Philippe, Meyer, Tim, Qin, Shukui, Ikeda, Masafumi, Xu, Ruocai, Edeline, Julien, Ryoo, Baek-Yeol, Ren, Zhenggang, Masi, Gianluca, Kwiatkowski, Mariusz, Lim, Ho Yeong, Kim, Jee Hyun, Breder, Valeriy, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, and Wang, Anran
- Subjects
- *
CLINICAL trials , *HEPATOCELLULAR carcinoma , *PROGRESSION-free survival , *STROKE , *PEMBROLIZUMAB , *GASTROINTESTINAL hemorrhage , *HEPATORENAL syndrome - Abstract
Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, α-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0·019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0·002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov , NCT03713593 , and is active but not recruiting. Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 66·0 years (IQR 57·0–72·0), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 32·1 months (IQR 29·4–35·3). Median overall survival was 21·2 months (95% CI 19·0–23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2–21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71–1·00; stratified log-rank p=0·023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 8·2 months (95% CI 6·4–8·4; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 8·0 months (6·3–8·2; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 0·87; 95% CI 0·73–1·02; stratified log-rank p=0·047). The most common treatment-related grade 3–4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]). In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation
- Author
-
Miltiadous, Oriana, Sia, Daniela, Hoshida, Yujin, Fiel, Maria Isabel, Harrington, Andrew N., Thung, Swan N., Tan, Poh Seng, Dong, Hui, Revill, Kate, Chang, Charissa Y., Roayaie, Sasan, Byrne, Thomas J., Mazzaferro, Vincenzo, Rakela, Jorge, Florman, Sander, Schwartz, Myron, and Llovet, Josep M.
- Published
- 2015
- Full Text
- View/download PDF
9. Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology.
- Author
-
Llovet, Josep M. and Heikenwalder, Mathias
- Published
- 2023
- Full Text
- View/download PDF
10. The new Editorial Team of JHEP Reports: From successful inception towards an established reputation
- Author
-
Llovet, Josep M.
- Published
- 2024
- Full Text
- View/download PDF
11. International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance
- Author
-
Singal, Amit G., Sanduzzi-Zamparelli, Marco, Nahon, Pierre, Ronot, Maxime, Hoshida, Yujin, Rich, Nicole, Reig, Maria, Vilgrain, Valerie, Marrero, Jorge, Llovet, Josep M., Parikh, Neehar D., and Villanueva, Augusto
- Published
- 2023
- Full Text
- View/download PDF
12. Hepatocellular carcinoma
- Author
-
Llovet, Josep M., Burroughs, Andrew, and Bruix, Jordi
- Published
- 2003
13. Applicability of adult-to-adult living donor liver transplantation
- Author
-
Rimola, Antoni, Llovet, Josep M., Navasa, Miquel, Bruix, Jordi, Londoño, María-Carlota, Fuster, Josep, and García-Valdecasas, Juan-Carlos
- Published
- 2005
- Full Text
- View/download PDF
14. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020).
- Author
-
Haber, Philipp K., Puigvehí, Marc, Castet, Florian, Lourdusamy, Vennis, Montal, Robert, Tabrizian, Parissa, Buckstein, Michael, Kim, Edward, Villanueva, Augusto, Schwartz, Myron, and Llovet, Josep M.
- Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have aimed at improving outcomes across disease stages. We aimed to analyze the current evidence and identify potential factors influencing response to therapies. We conducted a systematic review of phase III RCTs (2002–2020) across disease stages. A meta-analysis was designed to examine the relationship between etiology and outcome after systemic therapies with either tyrosine-kinase inhibitor (TKI)/antiangiogenic or immune checkpoint inhibitor (ICI) therapy. Out of 10,100 studies identified, 76 were phase III RCTs. Among them, a rigorous screening algorithm identified 49 with high quality including a total of 22,113 patients undergoing adjuvant (n = 7) and primary treatment for early (n = 2), intermediate (n = 7), and advanced (first-line, n = 21; second-line, n = 12) stages of disease. Nine of these trials were positive, 6 treatments have been adopted in guidelines (sorafenib [2 RCTs], lenvatinib, atezolizumab+bevacizumab, regorafenib, cabozantinib and ramucirumab), but 2 were not (adjuvant CIK cells and sorafenib plus hepatic arterial infusion with FOLFOX). Meta-analysis of 8 trials including 3739 patients revealed ICI therapy to be significantly more effective in patients with viral hepatitis compared with nonviral-related HCC, whereas no differences related to etiology were observed in patients treated with TKI/anti–vascular endothelial growth factor. Among 49 high-quality RCTs conducted in HCC during 2002–2020, 9 resulted in positive results. A meta-analysis of systemic therapies suggests that immunotherapies may be more effective in viral etiologies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Hepatitis B virus and hepatocellular carcinoma
- Author
-
Bruix, Jordi and Llovet, Josep M
- Published
- 2003
- Full Text
- View/download PDF
16. p27 Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma
- Author
-
Armengol, Carolina, Boix, Loreto, Bachs, Oriol, Solé, Manel, Fuster, Josep, Sala, Margarita, Llovet, Josep M, Rodés, Juan, and Bruix, Jordi
- Published
- 2003
- Full Text
- View/download PDF
17. Hepatocellular carcinoma: present status and future prospects
- Author
-
Llovet, Josep M and Beaugrand, Michel
- Published
- 2003
- Full Text
- View/download PDF
18. Interferon for the prevention of hepatocellular carcinoma
- Author
-
Bruix, Jordi, Sala, Margarita, and Llovet, Josep M.
- Published
- 2002
- Full Text
- View/download PDF
19. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
- Author
-
Bruix, Jordi, Sherman, Morris, Llovet, Josep M, Beaugrand, Michel, Lencioni, Riccardo, Burroughs, Andrew K, Christensen, Erik, Pagliaro, Luigi, Colombo, Massimo, and Rodés, Juan
- Published
- 2001
- Full Text
- View/download PDF
20. mRECIST for HCC: Performance and novel refinements.
- Author
-
Llovet, Josep M. and Lencioni, Riccardo
- Subjects
- *
PROGRESSION-free survival , *HEPATOCELLULAR carcinoma , *UNITS of measurement , *LANDSCAPE changes , *LIVER diseases - Abstract
In 2010, modified RECIST (mRECIST) criteria were proposed as a way of adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We intended to overcome some limitations of RECIST in measuring tumour shrinkage with local and systemic therapies, and also to refine the assessment of progression that could be misinterpreted with conventional RECIST 1.1, due to clinical events related to the natural progression of chronic liver disease (development of ascites, enlargement of lymph nodes, etc.). mRECIST has served its purpose since being adopted or included in clinical practice guidelines (European, American and Asian) for the management of HCC; it has also been instrumental for assessing response and time-to-event endpoints in several phase II and III investigations. Nowadays, mRECIST has become the standard tool for measurement of radiological endpoints at early/intermediate stages of HCC. At advanced stages, guidelines recommend both methods. mRECIST has been proven to capture higher objective response rates in tumours treated with molecular therapies and those responses have shown to be independently associated with better survival. With the advent of novel treatment approaches (i.e. immunotherapy) and combination therapies there is a need to further refine and clarify some concepts around the performance of mRECIST. Similarly, changes in the landscape of standard of care at advanced stages of the disease are pointing towards progression-free survival as a potential primary endpoint in some phase III investigations, as effective therapies applied beyond progression might mask overall survival results. Strict recommendations for adopting this endpoint have been reported. Overall, we review the performance of mRECIST during the last decade, incorporating novel clarifications and refinements in light of emerging challenges in the study and management of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
- Author
-
Teufel, Michael, Seidel, Henrik, Köchert, Karl, Meinhardt, Gerold, Finn, Richard S., Llovet, Josep M., and Bruix, Jordi
- Abstract
Background & Aims In a phase 3 trial (RESORCE), regorafenib increased overall survival compared with placebo in patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. In an exploratory study, we analyzed plasma and tumor samples from study participants to identify genetic, microRNA (miRNA), and protein biomarkers associated with response to regorafenib. Methods We obtained archived tumor tissues and baseline plasma samples from patients with HCC given regorafenib in the RESORCE trial. Baseline plasma samples from 499 patients were analyzed for expression of 294 proteins (DiscoveryMAP) and plasma samples from 349 patients were analyzed for levels of 750 miRNAs (miRCURY miRNA PCR). Tumor tissues from 7 responders and 10 patients who did not respond (progressors) were analyzed by next-generation sequencing (FoundationOne). Forty-six tumor tissues were analyzed for expression patterns of 770 genes involved in oncogenic and inflammatory pathways (PanCancer Immune Profiling). Associations between plasma levels of proteins and miRNAs and response to treatment (overall survival and time to progression) were evaluated using a Cox proportional hazards model. Results Decreased baseline plasma concentrations of 5 of 266 evaluable proteins (angiopoietin 1, cystatin B, the latency-associated peptide of transforming growth factor beta 1, oxidized low-density lipoprotein receptor 1, and C-C motif chemokine ligand 3; adjusted P ≤.05) were significantly associated with increased overall survival time after regorafenib treatment. Levels of these 5 proteins, which have roles in inflammation and/or HCC pathogenesis, were not associated with survival independently of treatment. Only 20 of 499 patients had high levels and a reduced survival time. Plasma levels of α-fetoprotein and c-MET were associated with poor outcome (overall survival) independently of regorafenib treatment only. We identified 9 plasma miRNAs (MIR30A, MIR122, MIR125B, MIR200A, MIR374B, MIR15B, MIR107, MIR320, and MIR645) whose levels significantly associated with overall survival time with regorafenib (adjusted P ≤.05). Functional analyses of these miRNAs indicated that their expression level associated with increased overall survival of patients with tumors of the Hoshida S3 subtype. Next-generation sequencing analyses of tumor tissues revealed 49 variants in 27 oncogenes or tumor suppressor genes. Mutations in CTNNB1 were detected in 3 of 10 progressors and VEGFA amplification in 1 of 7 responders. Conclusion We identified expression patterns of plasma proteins and miRNAs that associated with increased overall survival times of patients with HCC following treatment with regorafenib in the RESORCE trial. Levels of these circulating biomarkers and genetic features of tumors might be used to identify patients with HCC most likely to respond to regorafenib. ClinicalTrials.gov number NCT01774344. NCBI GEO accession numbers: mRNA data (NanoString): GSE119220 ; miRNA data (Exiqon): GSE119221 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
- Author
-
Llovet, Josep M, Real, Maria Isabel, Montana, Xavier, Planas, Ramon, Coll, Susana, Aponte, John, Ayuso, Carmen, Sala, Margarita, Muchart, Jordi, Sola, Ricard, Rodes, Joan, and Bruix, Jordi
- Subjects
Liver cancer -- Prognosis ,Postoperative care -- Evaluation - Published
- 2002
23. GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
- Author
-
Galle, Peter, Kudo, Masatoshi, Llovet, Josep M., Finn, Richard, Karwal, Mark, Denis, Pezet, Kim, Tae-You, Yang, Tsai-Sheng, Zagonel, Vittorina, Tomasek, Jiri, Phelip, Jean-Marc, Touchefeu, Yann, Koh, Su-Jin, Stirnimann, Guido, Wang, Chunxiao, Widau, Ryan, Hsu, Yanzhi, Abada, Paolo B., and Zhu, Andrew
- Published
- 2019
- Full Text
- View/download PDF
24. PS-048-Definition of aneuploidy profiles and their impact on tumour progression and immune features in hepatocellular carcinoma
- Author
-
Esteban-Fabró, Roger, Bassaganyas, Laia, Torrecilla, Sara, Moeini, Agrin, Franch-Expósito, Sebastià, Vila-Casadesús, Maria, Nadeu, Ferran, Cabellos, Laia, Sia, Daniela, Salaverria, Itziar, Pinyol, Roser, Camps, Jordi, Mazzaferro, Vincenzo, and Llovet, Josep M.
- Published
- 2019
- Full Text
- View/download PDF
25. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
- Author
-
Sia, Daniela, Jiao, Yang, Martinez-Quetglas, Iris, Kuchuk, Olga, Villacorta-Martin, Carlos, Castro de Moura, Manuel, Putra, Juan, Camprecios, Genis, Bassaganyas, Laia, Akers, Nicholas, Losic, Bojan, Waxman, Samuel, Thung, Swan N., Mazzaferro, Vincenzo, Esteller, Manel, Friedman, Scott L., Schwartz, Myron, Villanueva, Augusto, and Llovet, Josep M.
- Abstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors. Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data). Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs. Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
- Author
-
Sia, Daniela, Villanueva, Augusto, Friedman, Scott L., and Llovet, Josep M.
- Abstract
Primary liver cancer is the second leading cause of cancer-related death worldwide and therefore a major public health challenge. We review hypotheses of the cell of origin of liver tumorigenesis and clarify the classes of liver cancer based on molecular features and how they affect patient prognosis. Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other rare tumors, notably fibrolamellar carcinoma and hepatoblastoma. The molecular and clinical features of HCC versus iCCA are distinct, but these conditions have overlapping risk factors and pathways of oncogenesis. A better understanding of the cell types originating liver cancer can aid in exploring molecular mechanisms of carcinogenesis and therapeutic options. Molecular studies have identified adult hepatocytes as the cell of origin. These cells have been proposed to transform directly into HCC cells (via a sequence of genetic alterations), to dedifferentiate into hepatocyte precursor cells (which then become HCC cells that express progenitor cell markers), or to transdifferentiate into biliary-like cells (which give rise to iCCA). Alternatively, progenitor cells also give rise to HCCs and iCCAs with markers of progenitor cells. Advances in genome profiling and next-generation sequencing have led to the classification of HCCs based on molecular features and assigned them to categories such as proliferation–progenitor, proliferation–transforming growth factor β, and Wnt–catenin β1. iCCAs have been assigned to categories of proliferation and inflammation. Overall, proliferation subclasses are associated with a more aggressive phenotype and poor outcome of patients, although more specific signatures have refined our prognostic abilities. Analyses of genetic alterations have identified those that might be targeted therapeutically, such as fusions in the FGFR2 gene and mutations in genes encoding isocitrate dehydrogenases (in approximately 60% of iCCAs) or amplifications at 11q13 and 6p21 (in approximately 15% of HCCs). Further studies of these alterations are needed before they can be used as biomarkers in clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
- Author
-
Martinez-Quetglas, Iris, Pinyol, Roser, Dauch, Daniel, Torrecilla, Sara, Tovar, Victoria, Moeini, Agrin, Alsinet, Clara, Portela, Anna, Rodriguez-Carunchio, Leonardo, Solé, Manel, Lujambio, Amaia, Villanueva, Augusto, Thung, Swan, Esteller, Manel, Zender, Lars, and Llovet, Josep M.
- Abstract
Background & Aims Effective treatments are urgently needed for hepatocellular carcinoma (HCC), which is usually diagnosed at advanced stages. Signaling via the insulin-like growth factor (IGF) pathway is aberrantly activated in HCC by IGF2 overexpression. We aimed to elucidate the mechanism of IGF2 overexpression and its oncogenic activities and evaluate the anti-tumor effects of reducing IGF2 signaling. Methods We obtained 228 HCC samples from patients who underwent liver resection, 168 paired non-tumor adjacent cirrhotic liver samples, and 10 non-tumor liver tissues from patients undergoing resection for hepatic hemangioma. We analyzed gene expression, microRNA, and DNA methylation profiles for all samples, focusing on genes in the IGF signaling pathway. IGF2 was expressed in SNU449 and PLC5 HCC cells and knocked down with small hairpin RNAs in Hep3B and Huh7 cell lines. We analyzed these cells for proliferation, apoptosis, migration, and colony formation. We performed studies in mice engineered to express Myc and Akt1 in liver, which develop liver tumors, with or without hepatic expression of Igf2 . Mice with xenograft tumors grown from HCC cells were given a monoclonal antibody against IGF1 and IGF2 (xentuzumab), along with sorafenib; tumor growth was measured and tissues were analyzed by immunohistochemistry and immunoblots. Results Levels of IGF2 messenger RNA and protein were increased >20-fold in 15% of human HCC tissues compared with non-tumor liver tissues. Methylation at the fetal promoters of IGF2 was reduced in the HCC samples and cell lines that overexpressed IGF2, compared with those that did not overexpress this gene, and non-tumor tissues. Tumors that overexpressed IGF2 had gene expression patterns significantly associated with hepatic progenitor cell features, stellate cell activation, NOTCH signaling, and an aggressive phenotype ( P < .0001). In mice engineered to express Myc and Akt1 in liver, co-expression of Igf2 accelerated formation of liver tumors, compared to mice with livers expressing only Myc and Akt1 , and shortened survival times ( P = .02). The antibody xentuzumab blocked phosphorylation of IGF1 receptor in HCC cell lines and reduced their proliferation and colony formation. In mice with xenograft tumors, injection of xentuzumab, with or without sorafenib, slowed tumor growth and increased survival times compared to vehicle or sorafenib alone. Xentuzumab inhibited phosphorylation of IGF1 receptor and AKT and reduced decreased tumor vascularization compared with vehicle. Conclusions A large proportion of HCC samples were found to overexpress IGF2, via demethylation of its fetal promoter. Overexpression of IGF2 accelerates formation of liver tumors in mice with hepatic expression of MYC and AKT1, via activation of IGF1 receptor signaling. An antibody against IGF1 and IGF2 slows growth of xenograft tumors and increases survival of these mice. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
- Author
-
Lencioni, Riccardo, Llovet, Josep M., Han, Guohong, Tak, Won Young, Yang, Jiamei, Guglielmi, Alfredo, Paik, Seung Woon, Reig, Maria, Kim, Do Young, Chau, Gar-Yang, Luca, Angelo, del Arbol, Luis Ruiz, Leberre, Marie-Aude, Niu, Woody, Nicholson, Kate, Meinhardt, Gerold, and Bruix, Jordi
- Subjects
- *
SORAFENIB , *DOXORUBICIN , *LIVER cancer , *CHEMOEMBOLIZATION , *LIVER tumors , *PLACEBOS - Abstract
Background & Aims Transarterial chemoembolization with doxorubicin-eluting beads (DC Bead®; DEB-TACE) is effective in patients with Barcelona clinic liver cancer stage B hepatocellular carcinoma (HCC). The multikinase inhibitor sorafenib enhances overall survival (OS) and time-to-tumor progression (TTP) in patients with advanced HCC. This exploratory phase II trial tested the efficacy and safety of DEB-TACE plus sorafenib in patients with intermediate stage HCC. Methods Patients with intermediate stage multinodular HCC without macrovascular invasion (MVI) or extrahepatic spread (EHS) were randomized 1:1 to DEB-TACE (150 mg doxorubicin) plus sorafenib 400 mg twice daily or placebo. The primary endpoint was TTP by blinded central review. Secondary endpoints included time to MVI/EHS, OS, overall response rate (ORR) using modified response evaluation criteria in solid tumors, disease control rate (DCR), time to unTACEable progression (TTUP), and safety. Results Of 307 patients randomized, 154 received sorafenib and 153 received placebo. Median TTP for subjects receiving sorafenib plus DEB-TACE or placebo plus DEB-TACE was similar (169 vs . 166 days, respectively; hazard ratio (HR) 0.797, p = 0.072). Median time to MVI/EHS (HR 0.621, p = 0.076) and OS (HR 0.898, p = 0.29) had not been reached. The ORRs for patients in the sorafenib and placebo groups with post-baseline scans were 55.9% and 41.3%, respectively, and the DCRs were 89.2% and 76.1%, respectively. TTUP was lower with sorafenib than with placebo (HR 1.586; 95% confidence intervals, 1.200–2.096; median 95 vs . 224 days). No unexpected adverse events related to sorafenib were observed. Conclusion Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB-TACE alone. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression.
- Author
-
Fitamant, Julien, Kottakis, Filippos, Benhamouche, Samira, Tian, Helen S., Chuvin, Nicolas, Parachoniak, Christine A., Nagle, Julia M., Perera, Rushika M., Lapouge, Marjorie, Deshpande, Vikram, Zhu, Andrew X., Lai, Albert, Min, Bosun, Hoshida, Yujin, Avruch, Joseph, Sia, Daniela, Campreciós, Genís, McClatchey, Andrea I., Llovet, Josep M., and Morrissey, David
- Abstract
Summary Defective Hippo/YAP signaling in the liver results in tissue overgrowth and development of hepatocellular carcinoma (HCC). Here, we uncover mechanisms of YAP-mediated hepatocyte reprogramming and HCC pathogenesis. YAP functions as a rheostat in maintaining metabolic specialization, differentiation, and quiescence within the hepatocyte compartment. Increased or decreased YAP activity reprograms subsets of hepatocytes to different fates associated with deregulation of the HNF4A, CTNNB1, and E2F transcriptional programs that control hepatocyte quiescence and differentiation. Importantly, treatment with small interfering RNA-lipid nanoparticles (siRNA-LNPs) targeting YAP restores hepatocyte differentiation and causes pronounced tumor regression in a genetically engineered mouse HCC model. Furthermore, YAP targets are enriched in an aggressive human HCC subtype characterized by a proliferative signature and absence of CTNNB1 mutations. Thus, our work reveals Hippo signaling as a key regulator of the positional identity of hepatocytes, supports targeting of YAP using siRNA-LNPs as a paradigm of differentiation-based therapy, and identifies an HCC subtype that is potentially responsive to this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. Integration of genomic information in the clinical management of HCC.
- Author
-
Quetglas, Iris M., Moeini, Agrin, Pinyol, Roser, and Llovet, Josep M.
- Published
- 2014
- Full Text
- View/download PDF
31. A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection.
- Author
-
NAULT, JEAN-CHARLES, DE REYNIÉS, AURÉLIEN, VILLANUEVA, AUGUSTO, CALDERARO, JULIEN, REBOUISSOU, SANDRA, COUCHY, GABRIELLE, DECAENS, THOMAS, FRANCO, DOMINIQUE, IMBEAUD, SANDRINE, ROUSSEAU, FRANCIS, AZOULAY, DANIEL, SARIC, JEAN, BLANC, JEAN-FRÉDÉRIC, BALABAUD, CHARLES, BIOULAC-SAGE, PAULETTE, LAURENT, ALEXIS, LAURENT-PUIG, PIERRE, LLOVET, JOSEP M., and ZUCMAN-ROSSI, JESSICA
- Abstract
BACKGROUND & AIMS: Due to the phenotypic and molecular diversity of hepatocellular carcinomas (HCC), it is a challenge to determine a patient's prognosis. We aimed to identify new prognostic markers of patients with HCC treated by liver resection. METHODS: We collected 314 HCC samples from patients at Bordeaux (1998-2007) and Créteil (2003-2007) hospitals in France. We analyzed the gene expression patterns of the tumors and compared expression patterns with patient survival times. Using the coefficient and regression formula of the multivariate Cox model, we identified a "5-gene score" associated with survival times. This molecular score was then validated in 2 groups of patients from Europe and the United States (n = 213) and China (n = 221). RESULTS: The 5-gene score, based on combined expression level of HN1, RAN, RAMP3, KRT19, and TAF9, was associated with disease-specific survival times of 189 patients with resected HCC in Bordeaux (hazard ratio = 3.5; 95% confidence interval: 1.9-6.6; P < .0001). The association between the 5-gene score and disease-specific survival was validated in an independent cohort of 125 patients in Créteil (hazard ratio = 2.3; 95% confidence interval: 1.1-4.9; P < .0001). The 5-gene score more accurately predicted patient outcomes than gene expression signatures reported previously. In multivariate analyses, the 5-gene score was associated with disease-specific survival, independent of other clinical and pathology feature of HCC. Disease-specific survival was also predicted by combining data on microvascular invasion, the Barcelona Clinic Liver Cancer classification system, and the 5-gene score in a nomogram. The prognostic accuracy of the 5-gene score was further validated in European and US patients with hepatitis C, cirrhosis, and HCC (overall survival P = .002) and in Asian patients with HCC with hepatitis B (overall survival, P = .02). Combining the 5-gene score with the expression pattern of 186 genes in corresponding cirrhotic tissues increased its prognostic accuracy. CONCLUSIONS: The molecular $-gene score is associated with outcomes of patients with HCC treated by resection in different clinical settings worldwide. This new biomarker should be tested in clinical trials to stratify patients in therapeutic decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
32. Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis.
- Author
-
Hoshida, Yujin, Villanueva, Augusto, Sangiovanni, Angelo, Sole, Manel, Hur, Chin, Andersson, Karin L., Chung, Raymond T., Gould, Joshua, Kojima, Kensuke, Gupta, Supriya, Taylor, Bradley, Crenshaw, Andrew, Gabriel, Stacey, Minguez, Beatriz, Iavarone, Massimo, Friedman, Scott L., Colombo, Massimo, Llovet, Josep M., and Golub, Todd R.
- Subjects
GENE expression ,HEPATITIS C ,CIRRHOSIS of the liver ,LIVER cancer ,REGRESSION analysis ,PATIENTS - Abstract
Background & Aims: Cirrhosis affects 1% to 2% of the world population and is the major risk factor for hepatocellular carcinoma (HCC). Hepatitis C cirrhosis–related HCC is the most rapidly increasing cause of cancer death in the United States. Noninvasive methods have been developed to identify patients with asymptomatic early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients with newly diagnosed cirrhosis but without HCC. Methods: We performed gene expression profile analysis of formalin-fixed needle biopsy specimens from the livers of 216 patients with hepatitis C–related early-stage (Child–Pugh class A) cirrhosis who were prospectively followed up for a median of 10 years at an Italian center. We evaluated whether the 186-gene signature was associated with death, progression of cirrhosis, and development of HCC. Results: Fifty-five (25%), 101 (47%), and 60 (28%) patients were classified as having poor-, intermediate-, and good-prognosis signatures, respectively. In multivariable Cox regression modeling, the poor-prognosis signature was significantly associated with death (P = .004), progression to advanced cirrhosis (P < .001), and development of HCC (P = .009). The 10-year rates of survival were 63%, 74%, and 85% and the annual incidence of HCC was 5.8%, 2.2%, and 1.5% for patients with poor-, intermediate-, and good-prognosis signatures, respectively. Conclusions: A 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C–related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent the development of HCC. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
33. Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma.
- Author
-
Hernandez–Gea, Virginia, Toffanin, Sara, Friedman, Scott L., and Llovet, Josep M.
- Subjects
LIVER cancer ,CHEMOPREVENTION ,CANCER stem cells ,CANCER-related mortality ,VASCULAR endothelial growth factors ,FIBROBLAST growth factors ,CELLULAR signal transduction - Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third greatest cause of cancer-related death worldwide, and its incidence is increasing. Despite the significant improvement in management of HCC over the past 30 years, there are no effective chemoprevention strategies, and only one systemic therapy has been approved for patients with advanced tumors. This drug, sorafenib, acts on tumor cells and the stroma. HCC develops from chronically damaged tissue that contains large amounts of inflammation and fibrosis, which also promote tumor progression and resistance to therapy. Increasing our understanding of how stromal components interact with cancer cells and the signaling pathways involved could help identify new therapeutic and chemopreventive targets. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
34. Targeted Therapies for Hepatocellular Carcinoma.
- Author
-
Villanueva, Augusto and Llovet, Josep M.
- Subjects
LIVER cancer ,VASCULAR endothelial growth factors ,ONCOGENES ,BIOMARKERS ,COLON cancer ,MONOCLONAL antibodies ,RAPAMYCIN - Abstract
Unlike most solid tumors, the incidence and mortality of hepatocellular carcinoma (HCC) have increased in the United States and Europe in the past decade. Most patients are diagnosed at advanced stages, so there is an urgent need for new systemic therapies. Sorafenib, a tyrosine kinase inhibitor (TKI), has shown clinical efficacy in patients with HCC. Studies in patients with lung, breast, or colorectal cancers have indicated that the genetic heterogeneity of cancer cells within a tumor affect its response to therapeutics designed to target specific molecules. When tumor progression requires alterations in specific oncogenes (oncogene addiction), drugs that selectively block their products might slow tumor growth. However, no specific oncogene addictions are yet known to be implicated in HCC progression, so it is important to improve our understanding of its molecular pathogenesis. There are currently many clinical trials evaluating TKIs for HCC, including those tested in combination with (eg, erlotinib) or compared with (eg, linifanib) sorafenib as a first-line therapy. For patients who do not respond or are intolerant to sorafenib, TKIs such as brivanib, everolimus, and monoclonal antibodies (eg, ramucirumab) are being tested as second-line therapies. There are early stage trials investigating the efficacy for up to 60 reagents for HCC. Together, these studies might change the management strategy for HCC, and combination therapies might be developed for patients with advanced HCC. Identification of oncogenes that mediate tumor progression, and trials that monitor their products as biomarkers, might lead to personalized therapy; reagents that interfere with signaling pathways required for HCC progression might be used to treat selected populations, and thereby maximize the efficacy and cost benefit. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
35. A System of Classifying Microvascular Invasion to Predict Outcome After Resection in Patients With Hepatocellular Carcinoma.
- Author
-
Roayaie, Sasan, Blume, Iris N., Thung, Swan N., Guido, Maria, Fiel, Maria–Isabel, Hiotis, Spiros, Labow, Daniel M., Llovet, Josep M., and Schwartz, Myron E.
- Subjects
LIVER cancer patients ,MICROCIRCULATION ,HEALTH outcome assessment ,SURGERY ,SURGICAL complications ,CANCER relapse ,SURVIVAL analysis (Biometry) ,TOMOGRAPHY ,CANCER risk factors - Abstract
Background & Aims: Hepatocellular carcinoma (HCC) recurs in approximately 70% of cases after resection. Vascular invasion by tumor cells can be classified as gross or microscopic (microvascular invasion [mVI]) and is a risk factor for recurrence. We examined a large cohort of patients with HCC who were treated by resection to identify features of mVI that correlated with recurrence and survival. Methods: We reviewed the records of all HCC resections performed at the Mount Sinai School of Medicine between January 1990 and March 2006 to identify those with mVI, established by histologic analysis. The numbers and sizes of vessels invaded, invasion of a vessel with a muscular wall, distance from the tumor, and satellite nodules were recorded. Results: Of the 384 patients who underwent resection for HCC, 131 (34.1%) met the entry criteria. The median follow-up period was 28.9 months. There were 68 recurrences and 54 deaths. In multivariate analysis, invasion of a vessel with a muscular wall predicted recurrence (hazard ratio, 1.8; P = .02), and invasion of a vessel with a muscular wall (hazard ratio, 2.2; P = .018) and invasion of a vessel that was more than 1 cm from the tumor (hazard ratio, 2.1; P = .015) predicted survival. A risk score that assigned points for the presence of each variable correlated with recurrence (P = .028) and survival (P < .0001). Conclusions: A novel classification system that includes invasion of a vessel with a muscular wall and invasion of a vessel that is more than 1 cm from the tumor can accurately predict risk of recurrence and survival of patients with mVI after resection of HCC. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular Carcinoma.
- Author
-
Marrero, Jorge A., Feng, Ziding, Wang, Yinghui, Nguyen, Mindie H., Befeler, Alex S., Roberts, Lewis R., Reddy, K. Rajender, Harnois, Denise, Llovet, Josep M., Normolle, Daniel, Dalhgren, Jackie, Chia, David, Lok, Anna S., Wagner, Paul D., Srivastava, Sudhir, and Schwartz, Myron
- Subjects
ALPHA fetoproteins ,LECTINS ,LIVER cancer ,CIRRHOSIS of the liver ,BIOMARKERS ,CASE-control method ,ACADEMIC medical centers ,LIVER ,PATIENTS ,MAGNETIC resonance imaging - Abstract
Background & Aims: α-Fetoprotein (AFP) is widely used as a surveillance test for hepatocellular carcinoma (HCC) among patients with cirrhosis. Des-γ carboxy-prothrombin (DCP) and lectin-bound AFP (AFP-L3%) are potential surveillance tests for HCC. The aims of this study were to determine performance of DCP and AFP-L3% for the diagnosis of early HCC; whether they complement AFP; and what factors affect DCP, AFP-L3%, or AFP levels. Methods: We conducted a large phase 2 biomarker case-control study in 7 academic medical centers in the United States. Controls were patients with compensated cirrhosis and cases were patients with HCC. AFP, DCP, and AFP-L3% levels were measured blinded to clinical data in a central reference laboratory. Results: A total of 836 patients were enrolled: 417 (50%) were cirrhosis controls and 419 (50%) were HCC cases, of which 208 (49.6%) had early stage HCC (n = 77 very early, n = 131 early). AFP had the best area under the receiver operating characteristic curve (0.80, 95% confidence interval [CI]: 0.77–0.84), followed by DCP (0.72, 95% CI: 0.68–0.77) and AFP-L3% (0.66, 95% CI: 0.62–0.70) for early stage HCC. The optimal AFP cutoff value was 10.9 ng/mL leading to a sensitivity of 66%. When only those with very early HCC were evaluated, the area under the receiver operating characteristic curve for AFP was 0.78 (95% CI: 0.72–0.85) leading to a sensitivity of 65% at the same cutoff. Conclusions: AFP was more sensitive than DCP and AFP-L3% for the diagnosis of early and very early stage HCC at a new cutoff of 10.9 ng/mL. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
37. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
- Author
-
Mazzaferro, Vincenzo, Llovet, Josep M, Miceli, Rosalba, Bhoori, Sherrie, Schiavo, Marcello, Mariani, Luigi, Camerini, Tiziana, Roayaie, Sasan, Schwartz, Myron E, Grazi, Gian Luca, Adam, René, Neuhaus, Peter, Salizzoni, Mauro, Bruix, Jordi, Forner, Alejandro, De Carlis, Luciano, Cillo, Umberto, Burroughs, Andrew K, Troisi, Roberto, and Rossi, Massimo
- Subjects
- *
LIVER transplantation , *LIVER cancer patients , *SURVIVAL analysis (Biometry) , *TUMORS , *METASTASIS , *MEDICAL centers - Abstract
Summary: Background: Patients undergoing liver transplantation for hepatocellular carcinoma within the Milan criteria (single tumour ≤5 cm in size or ≤3 tumours each ≤3 cm in size, and no macrovascular invasion) have an excellent outcome. However, survival for patients with cancers that exceed these criteria remains unpredictable and access to transplantation is a balance of maximising patients'' chances of cure and organ availability. The aim of this study was to explore the survival of patients with tumours that exceed the Milan criteria, to assess whether the criteria could be less restrictive, enabling more patients to qualify as transplant candidates, and to derive a prognostic model based on objective tumour characteristics, to see whether the Milan criteria could be expanded. Methods: Data on patients who underwent transplantation for hepatocellular carcinoma despite exceeding Milan criteria at different centres were recorded via a web-based survey completed by specialists from each centre. The survival of these patients was correlated retrospectively with the size of the largest tumour nodule, number of nodules, and presence or absence of microvascular invasion detected at pathology. Contoured multivariable regression Cox models produced survival estimates by means of different combinations of the covariates. The primary aim of this study was to derive a prognostic model of overall survival based on tumour characteristics, according to the main parameters used in the Tumour Node Metastasis classification. The secondary aim was the identification of a subgroup of patients with hepatocellular carcinoma exceeding the Milan criteria, who achieved a 5-year overall survival of at least 70%—ie, similar to the outcome expected for patients who meet the Milan criteria. Findings: Over a 10-month period, between June 25, 2006, and April 3, 2007, data for 1556 patients who underwent transplantation for hepatocellular carcinoma were entered on the database by 36 centres. 1112 patients had hepatocellular carcinoma exceeding Milan criteria and 444 patients had hepatocellular carcinoma shown not to exceed Milan criteria at post-transplant pathology review. In the group of patients with hepatocellular carcinomas exceeding the criteria, the median size of the largest nodule was 40 mm (range 4–200) and the median number of nodules was four (1–20). 454 of 1112 patients (41%) had microvascular invasion and, for those transplanted outside the Milan criteria, 5-year overall survival was 53·6% (95% CI 50·1–57·0), compared with 73·3% (68·2–77·7) for those that met the criteria. Hazard ratios (HR) associated with increasing values of size and number were 1·34 (1·25–1·44) and 1·51 (1·21–1·88), respectively. The effect was linear for size, whereas for number of tumours, the effect tended to plateau above three tumours. The effect of tumour size and number on survival was mediated by recurrence (b=0·08, SE=0·12, p=0·476). The presence of microvascular invasion doubled HRs in all scenarios. The 283 patients without microvascular invasion, but who fell within the Up-to-seven criteria (hepatocellular carcinomas with seven as the sum of the size of the largest tumour [in cm] and the number of tumours) achieved a 5-year overall survival of 71·2% (64·3–77·0). Interpretation: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual (yes/no) approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria. Funding: Specific funding was not used to do this study. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
38. Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma.
- Author
-
Yea, Steven, Narla, Goutham, Zhao, Xiao, Garg, Rakhi, Tal–Kremer, Sigal, Hod, Eldad, Villanueva, Augusto, Loke, Johnny, Tarocchi, Mirko, Akita, Kunihara, Shirasawa, Senji, Sasazuki, Takehiko, Martignetti, John A., Llovet, Josep M., and Friedman, Scott L.
- Subjects
RENIN-angiotensin system ,CANCER cell growth regulation ,LIVER cancer ,TUMOR suppressor genes - Abstract
Background & Aims: Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer worldwide and the third most lethal. Dysregulation of alternative splicing underlies a number of human diseases, yet its contribution to liver cancer has not been explored fully. The Krüppel-like factor 6 (KLF6) gene is a zinc finger transcription factor that inhibits cellular growth in part by transcriptional activation of p21. KLF6 function is abrogated in human cancers owing to increased alternative splicing that yields a dominant-negative isoform, KLF6 splice variant 1 (SV1), which antagonizes full-length KLF6–mediated growth suppression. The molecular basis for stimulation of KLF6 splicing is unknown. Methods: In human HCC samples and cell lines, we functionally link oncogenic Ras signaling to increased alternative splicing of KLF6 through signaling by phosphatidylinositol-3 kinase and Akt, mediated by the splice regulatory protein ASF/SF2. Results: In 67 human HCCs, there is a significant correlation between activated Ras signaling and increased KLF6 alternative splicing. In cultured cells, Ras signaling increases the expression of KLF6 SV1, relative to full-length KLF6, thereby enhancing proliferation. Abrogation of oncogenic Ras signaling by small interfering RNA (siRNA) or a farnesyl-transferase inhibitor decreases KLF6 SV1 and suppresses growth. Growth inhibition by farnesyl-transferase inhibitor in transformed cell lines is overcome by ectopic expression of KLF6 SV1. Down-regulation of the splice factor ASF/SF2 by siRNA increases KLF6 SV1 messenger RNA levels. KLF6 alternative splicing is not coupled to its transcriptional regulation. Conclusions: Our findings expand the role of Ras in human HCC by identifying a novel mechanism of tumor-suppressor inactivation through increased alternative splicing mediated by an oncogenic signaling cascade. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
39. A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis.
- Author
-
Llovet, Josep M., Chen, Yingbei, Wurmbach, Elisa, Roayaie, Sasan, Fiel, M. Isabel, Schwartz, Myron, Thung, Swan N., Khitrov, Gregory, Zhang, Weijia, Villanueva, Augusto, Battiston, Carlo, Mazzaferro, Vincenzo, Bruix, Jordi, Waxman, Samuel, and Friedman, Scott L.
- Subjects
LIVER cancer ,DYSPLASIA ,POLYMERASE chain reaction ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Background & Aims: Small liver nodules ∼2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC). Methods: The transcriptional profiles of 55 candidate genes were assessed by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) in 17 dysplastic nodules (diameter, 10 mm) and 20 early HCC (diameter, 18 mm) from HCV cirrhotic patients undergoing resection/transplantation and 10 nontumoral cirrhotic tissues and 10 normal liver tissues. Candidate genes were confirmed by quantitative RT-PCR in 20 advanced HCCs and by immunohistochemistry in 75 samples and validated in an independent set of 29 samples (dysplastic nodules [10] and small HCC [19; diameter, 20 mm]). Results: Twelve genes were significantly, differentially expressed in early HCCs compared with dysplastic nodules (>2-fold change; area under the receiver operating characteristic curve ≥0.8): this included TERT, GPC3, gankyrin, survivin, TOP2A, LYVE1, E-cadherin, IGFBP3, PDGFRA, TGFA, cyclin D1, and HGF. Logistic regression analysis identified a 3-gene set including GPC3 (18-fold increase in HCC, P = .01), LYVE1 (12-fold decrease in HCC, P = .0001), and survivin (2.2-fold increase in HCC, P = .02), which had a discriminative accuracy of 94%. The validity of the gene signature was confirmed in a prospective testing set. GPC3 immunostaining was positive in all HCCs and negative in dysplastic nodules (22/22 vs 0/14, respectively, P < .001). Nuclear staining for survivin was positive in 12 of 13 advanced HCC cases and in 1 of 9 early tumors. Conclusions: Molecular data based on gene transcriptional profiles of a 3-gene set allow a reliable diagnosis of early HCC. Immunostaining of GPC3 confirms the diagnosis of HCC. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
40. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing
- Author
-
Fattovich, Giovanna and Llovet, Josep M.
- Published
- 2006
- Full Text
- View/download PDF
41. Hepatocellular Carcinoma: Patients With Increasing Alpha-Fetoprotein But No Mass on Ultrasound.
- Author
-
Llovet, Josep M.
- Published
- 2006
- Full Text
- View/download PDF
42. Percutaneous ethanol injection for hepatocellular carcinoma:Alive or dead?
- Author
-
Lencioni, Riccardo and Llovet, Josep M.
- Published
- 2005
- Full Text
- View/download PDF
43. Gene expression profiles in hepatocellular carcinoma: not yet there
- Author
-
Llovet, Josep M. and Wurmbach, Elisa
- Published
- 2004
- Full Text
- View/download PDF
44. Focal Gains of VEGFA: Candidate Predictors of Sorafenib Response in Hepatocellular Carcinoma.
- Author
-
Llovet, Josep?M.
- Subjects
- *
LIVER cancer , *VASCULAR endothelial growth factors , *PHENYLUREA compounds , *PARACRINE mechanisms , *HEPATOCYTE growth factor , *CANCER invasiveness - Abstract
Focal amplifications in 6p21 containing the VEGFA locus occur in 7%–10% of hepatocellular carcinoma (HCC). A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression. HCC patients with VEGFA amplification are distinctly sensitive to sorafenib. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
45. Chemoembolization for intermediate HCC: Is there proof of survival benefit?
- Author
-
Forner, Alejandro, Llovet, Josep M., and Bruix, Jordi
- Published
- 2012
- Full Text
- View/download PDF
46. Hepatocellular Carcinoma Enters the Sequencing Era.
- Author
-
Villanueva, Augusto, Hoshida, Yujin, and Llovet, Josep M.
- Published
- 2011
- Full Text
- View/download PDF
47. microRNAs and the MYC Network: A Major Piece in the Puzzle of Liver Cancer.
- Author
-
Toffanin, Sara, Alsinet, Clara, Cornella, Helena, Sia, Daniela, and Llovet, Josep M.
- Published
- 2011
- Full Text
- View/download PDF
48. Hippo Tumor Supressor Pathway: Novel Implications for the Treatment of Hepatocellular Carcinoma.
- Author
-
Lachenmayer, Anja, Hoshida, Yujin, and Llovet, Josep M.
- Published
- 2010
- Full Text
- View/download PDF
49. miRNA Delivery: Emerging Therapy for Hepatocellular Carcinoma.
- Author
-
Toffanin, Sara, Villanueva, Augusto, and Llovet, Josep M.
- Published
- 2010
- Full Text
- View/download PDF
50. Current management of liver cancer.
- Author
-
Lopez, Patricia M., Patel, Pruthvi, Uva, Pablo, Villanueva, Augusto, and Llovet, Josep M.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.